13q12.2 deletions and FLT3 overexpression in acute leukemias.
作者信息
Poubel Caroline Pires, Boroni Mariana, Emerenciano Mariana
机构信息
Division of Clinical Research and.
Bioinformatics and Computational Biology Laboratory, Research Center, Instituto Nacional de Câncer (INCA), Rio de Janeiro, Brazil.
出版信息
Blood Adv. 2021 Apr 27;5(8):2075-2078. doi: 10.1182/bloodadvances.2020003643.
Abstract
摘要
相似文献
1
13q12.2 deletions and FLT3 overexpression in acute leukemias.
Blood Adv. 2021 Apr 27;5(8):2075-2078. doi: 10.1182/bloodadvances.2020003643.
2
13q12.2 deletions in acute lymphoblastic leukemia lead to upregulation of FLT3 through enhancer hijacking.
Blood. 2020 Aug 20;136(8):946-956. doi: 10.1182/blood.2019004684.
3
Deletions in BCP-ALL result in a TAD more FLT3.
Blood. 2020 Aug 20;136(8):919-920. doi: 10.1182/blood.2020006607.
4
Expression of the FMS/KIT-like gene FLT3 in human acute leukemias of the myeloid and lymphoid lineages.
Blood. 1992 Nov 15;80(10):2584-93.
5
FLT3-ITD and CD135 Over-Expression are Frequent Findings of Poor Survival in Adult Patients with Acute Leukemias.
Arch Med Res. 2021 Feb;52(2):217-223. doi: 10.1016/j.arcmed.2020.10.013. Epub 2020 Oct 24.
6
Abnormalities of chromosome bands 13q12 to 13q14 in childhood acute lymphoblastic leukemia.
J Clin Oncol. 2000 Nov 15;18(22):3837-44. doi: 10.1200/JCO.2000.18.22.3837.
7
Translocation t(8;13)(p11;q11-12) in stem cell leukemia/lymphoma of T-cell and myeloid lineages.
Genes Chromosomes Cancer. 1995 Feb;12(2):148-51. doi: 10.1002/gcc.2870120210.
8
Activating FLT3 mutations in CD117/KIT(+) T-cell acute lymphoblastic leukemias.
Blood. 2004 Jul 15;104(2):558-60. doi: 10.1182/blood-2004-01-0168. Epub 2004 Mar 25.
9
IMC-EB10, an anti-FLT3 monoclonal antibody, prolongs survival and reduces nonobese diabetic/severe combined immunodeficient engraftment of some acute lymphoblastic leukemia cell lines and primary leukemic samples.
Cancer Res. 2006 May 1;66(9):4843-51. doi: 10.1158/0008-5472.CAN-06-0018.
10
FLT3 mutations in childhood acute lymphoblastic leukemia.
Blood. 2004 May 1;103(9):3544-6. doi: 10.1182/blood-2003-07-2441. Epub 2003 Dec 11.
本文引用的文献
1
Deletions in BCP-ALL result in a TAD more FLT3.
Blood. 2020 Aug 20;136(8):919-920. doi: 10.1182/blood.2020006607.
2
13q12.2 deletions in acute lymphoblastic leukemia lead to upregulation of FLT3 through enhancer hijacking.
Blood. 2020 Aug 20;136(8):946-956. doi: 10.1182/blood.2019004684.
3
FLT3 overexpression in acute leukaemias: New insights into the search for molecular mechanisms.
Biochim Biophys Acta Rev Cancer. 2019 Aug;1872(1):80-88. doi: 10.1016/j.bbcan.2019.06.001. Epub 2019 Jun 12.
4
Advances in biology of acute lymphoblastic leukemia (ALL) and therapeutic implications.
Am J Blood Res. 2018 Dec 10;8(4):29-56. eCollection 2018.
5
FLT3 pathway is a potential therapeutic target for PRC2-mutated T-cell acute lymphoblastic leukemia.
Blood. 2018 Dec 6;132(23):2520-2524. doi: 10.1182/blood-2018-04-845628. Epub 2018 Oct 3.
6
High expression of FLT3 is a risk factor in leukemia.
Mol Med Rep. 2018 Feb;17(2):2885-2892. doi: 10.3892/mmr.2017.8232. Epub 2017 Dec 8.
7
Comprehensive performance comparison of high-resolution array platforms for genome-wide Copy Number Variation (CNV) analysis in humans.
BMC Genomics. 2017 Apr 24;18(1):321. doi: 10.1186/s12864-017-3658-x.
8
RNA binding protein MSI2 positively regulates FLT3 expression in myeloid leukemia.
Leuk Res. 2017 Mar;54:47-54. doi: 10.1016/j.leukres.2017.01.015. Epub 2017 Jan 11.
9
Comprehensive genomic analysis reveals FLT3 activation and a therapeutic strategy for a patient with relapsed adult B-lymphoblastic leukemia.
Exp Hematol. 2016 Jul;44(7):603-13. doi: 10.1016/j.exphem.2016.04.011. Epub 2016 May 13.
10
The dual epigenetic role of PRMT5 in acute myeloid leukemia: gene activation and repression via histone arginine methylation.
Leukemia. 2016 Apr;30(4):789-99. doi: 10.1038/leu.2015.308. Epub 2015 Nov 5.
Zotero 插件